瑞他鲁肽对2型糖尿病患者体成分的影响:一项2期双盲平行组安慰剂对照随机试验的子研究
这项2期双盲随机对照试验在美国42个医学中心进行,纳入189名2型糖尿病成人患者,评估瑞他鲁肽与安慰剂及度拉糖肽相比对体成分的影响。第36周时,瑞他鲁肽4mg、8mg和12mg组总脂肪量较基线的降幅显著大于安慰剂,不良事件组间相似。
要点
- 瑞他鲁肽8mg(汇总)组总脂肪量较基线降低26.1%,12mg组降低23.2%,4mg(汇总)组降低15.2%。
- 与安慰剂相比,瑞他鲁肽4mg(汇总)组总脂肪量最小二乘均值变化为-10.7(95%CI -17.2至-4.2,p=0.0013)。
- 瑞他鲁肽8mg(汇总)组和12mg组与安慰剂相比总脂肪量变化分别为-21.6(95%CI -27.1至-16.1,p<0.0001)和-18.7(95%CI -25.1至-12.3,p<0.0001)。
核心结论
- 在2型糖尿病成人中,与安慰剂和度拉糖肽相比,瑞他鲁肽显著改善了总身体脂肪量的减少。
- 瘦体重丢失占体重丢失的比例与其他肥胖治疗方法相似。
- 这些发现可能提供 reassurance,即尽管总体体重减轻增加,瑞他鲁肽并未导致更大比例的瘦体重丢失。
研究设计与样本
- 这项2期、双盲、平行组、安慰剂对照、随机对照试验在美国42个医学中心进行。
- 纳入标准为18-75岁2型糖尿病成人,HbA1c 7.0-10.5%,体重稳定,BMI 25-50 kg/m2。
- 参与者按2:2:2:1:1:1:1:2比例随机分配至每周皮下注射安慰剂、度拉糖肽1.5mg或瑞他鲁肽0.5mg、4mg(2mg起始剂量)、4mg(4mg起始剂量)、8mg(2mg起始剂量)、8mg(4mg起始剂量)或12mg。
- 体成分子研究纳入189名参与者:安慰剂组29人,瑞他鲁肽0.5mg组32人,瑞他鲁肽4mg组(汇总)31人,瑞他鲁肽8mg组(汇总)33人,瑞他鲁肽12mg组30人,度拉糖肽1.5mg组34人。
- 预先设定的主要子研究终点为通过双能X射线吸收测定法(DXA)测量的总脂肪量从基线至第36周的百分比变化。
主要发现
- 总脂肪量较基线的百分比降低:瑞他鲁肽0.5mg组4.9%(SE 1.4%),瑞他鲁肽4mg(汇总)组15.2%(3.2%),瑞他鲁肽8mg(汇总)组26.1%(2.5%),瑞他鲁肽12mg组23.2%(3.0%),度拉糖肽组2.6%(1.6%),安慰剂组4.5%(1.2%)。
- 与安慰剂相比,总脂肪量较基线的最小二乘均值变化:瑞他鲁肽0.5mg组-0.4(95%CI -4.0至3.2,p=0.83),瑞他鲁肽4mg(汇总)组-10.7(95%CI -17.2至-4.2,p=0.0013),瑞他鲁肽8mg(汇总)组-21.6(95%CI -27.1至-16.1,p<0.0001),瑞他鲁肽12mg组-18.7(95%CI -25.1至-12.3,p<0.0001)。
- 严重不良事件:安慰剂组29人中2人(7%),瑞他鲁肽0.5mg组32人中2人(6%),瑞他鲁肽4mg组31人中0人,瑞他鲁肽8mg组33人中3人(9%),瑞他鲁肽12mg组30人中1人(3%),度拉糖肽组34人中0人。
- 胃肠道事件是最常报告的不良事件,未报告死亡。
关键数值与推荐
- 主要子研究终点为总脂肪量从基线至第36周的百分比变化,通过DXA测量。
- 疗效分析纳入所有随机分配且具有非缺失DXA扫描的参与者,使用停药前在治疗中的数据。
- 安全性分析纳入所有至少接受一剂研究药物的参与者。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Retatrutide, a glucose-dependent insulinotropic polypeptide, glucagon-like peptide-1, and glucagon receptor agonist, has demonstrated robust glucose and bodyweight reductions in participants with type 2 diabetes. This substudy assessed percent change from baseline to week 36 in total body fat mass versus placebo and dulaglutide. METHODS: This phase 2, double-blind, parallel-group, placebo-controlled, randomised controlled trial was done in 42 medical centres in the USA. Eligible participants were adults aged 18-75 years with type 2 diabetes, HbA1c of 7·0-10·5%, stable bodyweight, and BMI of 25-50 kg/m2. Eligible participants were randomly assigned in a 2:2:2:1:1:1:1:2 ratio to once-weekly subcutaneous placebo, dulaglutide 1·5 mg, or retatrutide 0·5 mg, 4 mg (2 mg initial dose), 4 mg (4 mg initial dose), 8 mg (2 mg initial dose), 8 mg (4 mg initial dose), or 12 mg. The prespecified primary substudy endpoint was percent change from baseline to week 36 in total fat mass, as measured by dual-energy X-ray absorptiometry (DXA). Regression methods with on-treatment data before study drug discontinuation from all randomly assigned participants with non-missing DXA scans were included in efficacy analysis. All participants who received at least one dose of study drug were included in the safety analysis population. The completed trial is registered with ClinicalTrials.gov, NCT04867785. FINDINGS: Between May 13, 2021 and June 13, 2022, 534 participants were screened for inclusion into the main study. 253 were excluded and 281 participants were enrolled and randomly assigned to the main study. Of the main study participants, 189 participants were enrolled to the body composition substudy (29 in the placebo group, 32 in the retatrutide 0·5 mg group, 31 in the retatrutide 4 mg groups [pooled], 33 in the retatrutide 8 mg group [pooled], 30 in the retatrutide 12 mg group, and 34 in the dulaglutide 1·5 mg group). Of these, 155 had a baseline DXA scan and 103 completed treatment and both baseline and week 36 DXA scans. 105 (56%) of 189 participants were female and 84 (44%) were male. 160 (85%) of 189 participants were White, 24 (13%) were Black, and five (3%) were Asian. Percent reduction from baseline in total fat mass was 4·9% (SE 1·4%) with retatrutide 0·5 mg, 15·2% (3·2%) with retatrutide 4 mg (pooled), 26·1% (2·5%) with retatrutide 8 mg (pooled), 23·2% (3·0%) with retatrutide 12 mg, 2·6% (1·6%) with dulaglutide, and 4·5% (1·2%) with placebo. Least squares mean change from baseline in total fat mass compared to placebo was -0·4 (95% CI -4·0 to 3·2, p=0·83 with retatrutide 0·5 mg, -10·7 (-17·2 to -4·2, p=0·0013) with retatrutide 4 mg (pooled), -21·6 (-27·1 to -16·1, p<0·0001) with retatrutide 8 mg (pooled), and -18·7 (-25·1 to -12·3, p<0·0001) with retatrutide 12 mg. Adverse events were similar between groups. Serious adverse events occurred in two (7%) of 29 participants in the placebo group, two (6%) of 32 participants in the retatrutide 0·5 mg group, zero of 31 participants in the retatrutide 4 mg group, three (9%) of 33 participants in the retatrutide 8 mg group, one (3%) of 30 participants in the retatrutide 12 mg group, and zero of 34 participants in the dulaglutide group. Gastrointestinal events were the most frequently reported adverse events, and no deaths were reported. INTERPRETATION: In adults with type 2 diabetes, retatrutide significantly improved total body fat mass reduction compared with placebo and dulaglutide. The proportion of lean mass loss to weight loss was similar to other obesity treatments. These findings could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss. FUNDING: The study was funded by Eli Lilly and Company.
引用
- Coskun T, Wu Q, Schloot NC, et al. Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2, double-blind, parallel-group, placebo-controlled, randomised trial. Lancet Diabetes Endocrinol. 2025. PMID: 40609566. doi:10.1016/S2213-8587(25)00092-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。